NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: C000000258

Registered date:05/10/2005

Effects of octreotide LAR treatment on QOL, clinical symptoms and endocrinological data in patients with acromegaly or pituitary gigantism

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedacromegaly and pituitary gigantism
Date of first enrollment2005/10/01
Target sample size50
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Octreotide LAR 10mg-40mg

Outcome(s)

Primary Outcome1. QOL(SF-36) 2. Clinical symptom(headache, sweating, arthralgia, carpal-tunnel syndrome, and other clinical symptoms) 3. Serum GH 4. Serum IGF-1
Secondary Outcome1. Complication(blood pressure, glucose tolerance status, dyslipidemia, and cardiovascular diseases 2. Adverse events

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1) Patients who have previous history of hypersensitivity for elements of Octreotide. 2) Patients whose serum bilirubin or serum creatinine concentration exceeds three times of the upper level of normal ranges. 3) Patients whose AST(GOT) or ALT(GPT) concentration exceeds five times of the upper level of normal ranges.

Related Information

Contact

public contact
Name Soji Kasayama
Address 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan Japan
Telephone 06-6879-3831
E-mail kasayama@imed3.med.osaka-u.ac.jp
Affiliation Osaka University Graduate School of Medicine Department of Medicine (Endaocrinology and Metabolism)(C-4)
scientific contact
Name Soji Kasayama
Address 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan Japan
Telephone 06-6879-3831
E-mail
Affiliation Osaka University Graduate School of Medicine Department of Medicine (Endocrinology and Metabolism)(C-4)